The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary.
David N. Louis,Arie Perry,Guido Reifenberger,Andreas von Deimling,Dominique Figarella-Branger,Webster K. Cavenee,Hiroko Ohgaki,Otmar D. Wiestler,Paul Kleihues,David W. Ellison +9 more
Reads0
Chats0
TLDR
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor and is hoped that it will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.Abstract:
The 2016 World Health Organization Classification of Tumors of the Central Nervous System is both a conceptual and practical advance over its 2007 predecessor. For the first time, the WHO classification of CNS tumors uses molecular parameters in addition to histology to define many tumor entities, thus formulating a concept for how CNS tumor diagnoses should be structured in the molecular era. As such, the 2016 CNS WHO presents major restructuring of the diffuse gliomas, medulloblastomas and other embryonal tumors, and incorporates new entities that are defined by both histology and molecular features, including glioblastoma, IDH-wildtype and glioblastoma, IDH-mutant; diffuse midline glioma, H3 K27M-mutant; RELA fusion-positive ependymoma; medulloblastoma, WNT-activated and medulloblastoma, SHH-activated; and embryonal tumour with multilayered rosettes, C19MC-altered. The 2016 edition has added newly recognized neoplasms, and has deleted some entities, variants and patterns that no longer have diagnostic and/or biological relevance. Other notable changes include the addition of brain invasion as a criterion for atypical meningioma and the introduction of a soft tissue-type grading system for the now combined entity of solitary fibrous tumor / hemangiopericytoma-a departure from the manner by which other CNS tumors are graded. Overall, it is hoped that the 2016 CNS WHO will facilitate clinical, experimental and epidemiological studies that will lead to improvements in the lives of patients with brain tumors.read more
Citations
More filters
Journal ArticleDOI
Assessment of Glioblastoma Response in the Era of Bevacizumab: Longstanding and Emergent Challenges in the Imaging Evaluation of Pseudoresponse.
Octavio Arevalo,Carolina Soto,Pejman Rabiei,Arash Kamali,Leomar Y. Ballester,Yoshua Esquenazi,Jay-Jiguang Zhu,Roy Riascos +7 more
TL;DR: The decrease in the enhancement intensity represents a change in the permeability properties of the blood brain barrier, and presumably, the switch of the tumor growth pattern to an infiltrative non-enhancing phenotype.
Journal ArticleDOI
Silencing LncRNA LOXL1-AS1 attenuates mesenchymal characteristics of glioblastoma via NF-κB pathway
Hongjin Wang,Li Li,Lin Yin +2 more
TL;DR: It is demonstrated that silencing LncRNA LOXL1-AS1 was a new regulator of NF-κB signaling pathway through repressing RELB directly, resulting in increased marker genes of PN subtype and decreased those of MES.
Journal ArticleDOI
MGMT promoter methylation level in newly diagnosed low-grade glioma is a predictor of hypermutation at recurrence
Radhika Mathur,Yalan Zhang,Matthew R. Grimmer,Matthew R. Grimmer,Chibo Hong,Michael Zhang,Saumya R. Bollam,Kevin Petrecca,Jennifer Clarke,Mitchel S. Berger,Joanna J. Phillips,Nancy Ann Oberheim-Bush,Annette M. Molinaro,Susan M. Chang,Joseph F. Costello +14 more
TL;DR: These findings reveal a mechanistic basis for observed differences in patient susceptibility to TMZ-driven hypermutation and establish MGMT promoter methylation level as a potential biomarker to inform clinical management of LGG patients, including monitoring and treatment decisions, by predicting risk ofhypermutation at recurrence.
Journal ArticleDOI
Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence.
Pierre-Olivier Guichet,Pierre-Olivier Guichet,Konstantin Masliantsev,Konstantin Masliantsev,Gaëlle Tachon,Gaëlle Tachon,Christos Petropoulos,Christos Petropoulos,Julie Godet,Delphine Larrieu,Serge Milin,Michel Wager,Michel Wager,Lucie Karayan-Tapon,Lucie Karayan-Tapon +14 more
TL;DR: The results showed that YAP1 could be a relevant prognostic biomarker and a potential therapeutic target in glioma and found that it may have prognostic significance for predicting patient survival, especially in low‐grade gliomas.
Journal ArticleDOI
Review: Challenges in the histopathological classification of ganglioglioma and DNT: microscopic agreement studies and a preliminary genotype-phenotype analysis.
Ingmar Blümcke,Ingmar Blümcke,Roland Coras,Annika K. Wefers,David Capper,David Capper,Eleonora Aronica,Albert J. Becker,Mrinalini Honavar,Thomas J Stone,Thomas J Stone,Thomas S. Jacques,Thomas S. Jacques,Hajime Miyata,Angelika Mühlebner,José Pimentel,Figen Soylemezoglu,Maria Thom +17 more
TL;DR: The Neuropathology Task Force of the International League Against Epilepsy recommends to further develop diagnostic panels for the integration of phenotype‐genotype analysis in order to reliably classify the spectrum of LEAT, carefully characterize clinically meaningful entities and make better use of published literature.
References
More filters
Journal ArticleDOI
Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas.
Daniel J. Brat,Roel G.W. Verhaak,Kenneth Aldape,W. K. Alfred Yung,Sofie R. Salama,Lee Cooper,Esther Rheinbay,C. Ryan Miller,Mark Vitucci,Olena Morozova,A. Gordon Robertson,Houtan Noushmehr,Peter W. Laird,Andrew D. Cherniack,Rehan Akbani,Jason T. Huse,Giovanni Ciriello,Laila M. Poisson,Jill S. Barnholtz-Sloan,Mitchel S. Berger,Cameron Brennan,Rivka R. Colen,Howard Colman,Adam E. Flanders,Caterina Giannini,Mia Grifford,Antonio Iavarone,Rajan Jain,Isaac Joseph,Jaegil Kim,Katayoon Kasaian,Tom Mikkelsen,Bradley A. Murray,Brian P. O'Neill,Lior Pachter,Donald W. Parsons,Carrie Sougnez,Erik P. Sulman,Scott R. VandenBerg,Erwin G. Van Meir,Andreas von Deimling,Hailei Zhang,Daniel Crain,Kevin Lau,David Mallery,Scott Morris,Joseph Paulauskis,Robert Penny,Troy Shelton,Mark E. Sherman,Peggy Yena,Aaron D. Black,Jay Bowen,Katie Dicostanzo,Julie M. Gastier-Foster,Kristen M. Leraas,Tara M. Lichtenberg,Christopher R. Pierson,Nilsa C. Ramirez,Cynthia Taylor,Stephanie Weaver,Lisa Wise,Erik Zmuda,Tanja M. Davidsen,John A. Demchok,Greg Eley,Martin L. Ferguson,Carolyn M. Hutter,Kenna R. Mills Shaw,Bradley A. Ozenberger,Margi Sheth,Heidi J. Sofia,Roy Tarnuzzer,Zhining Wang,Liming Yang,Jean C. Zenklusen,Brenda Ayala,Julien Baboud,Sudha Chudamani,Mark A. Jensen,Jia Liu,Todd Pihl,Rohini Raman,Yunhu Wan,Ye Wu,Adrian Ally,J. Todd Auman,Miruna Balasundaram,Saianand Balu,Stephen B. Baylin,Rameen Beroukhim,Moiz S. Bootwalla,Reanne Bowlby,Christopher A. Bristow,Denise Brooks,Yaron S.N. Butterfield,Rebecca Carlsen,Scott L. Carter,Lynda Chin,Andy Chu,Eric Chuah,Kristian Cibulskis,Amanda Clarke,Simon G. Coetzee,Noreen Dhalla,Timothy R. Fennell,Sheila A. Fisher,Stacey Gabriel,Gad Getz,Richard A. Gibbs,Ranabir Guin,Angela Hadjipanayis,D. Neil Hayes,Toshinori Hinoue,Katherine A. Hoadley,Robert A. Holt,Alan P. Hoyle,Stuart R. Jefferys,Steven J.M. Jones,Corbin D. Jones,Raju Kucherlapati,Phillip H. Lai,Eric S. Lander,Semin Lee,Lee Lichtenstein,Yussanne Ma,Dennis T. Maglinte,Harshad S. Mahadeshwar,Marco A. Marra,Michael Mayo,Shaowu Meng,Matthew Meyerson,Piotr A. Mieczkowski,Richard A. Moore,Lisle E. Mose,Andrew J. Mungall,Angeliki Pantazi,Michael Parfenov,Peter J. Park,Joel S. Parker,Charles M. Perou,Alexei Protopopov,Xiaojia Ren,Jeffrey Roach,Thais S. Sabedot,Jacqueline E. Schein,Steven E. Schumacher,Jonathan G. Seidman,Sahil Seth,Hui Shen,Janae V. Simons,Payal Sipahimalani,Matthew G. Soloway,Xingzhi Song,Huandong Sun,Barbara Tabak,Angela Tam,Donghui Tan,Jiabin Tang,Nina Thiessen,Timothy J. Triche,David Van Den Berg,Umadevi Veluvolu,Scot Waring,Daniel J. Weisenberger,Matthew D. Wilkerson,Tina Wong,Junyuan Wu,Liu Xi,Andrew Wei Xu,Lixing Yang,Travis I. Zack,Jianhua Zhang,B. Arman Aksoy,Harindra Arachchi,Chris Benz,Brady Bernard,Daniel E. Carlin,Juok Cho,Daniel DiCara,Scott Frazer,Gregory N. Fuller,Jianjiong Gao,Nils Gehlenborg,David Haussler,David I. Heiman,Lisa Iype,Anders Jacobsen,Zhenlin Ju,Sol Katzman,Hoon Kim,Theo A. Knijnenburg,Richard Kreisberg,Michael S. Lawrence,William M. Lee,Kalle Leinonen,Pei Lin,Shiyun Ling,Wen-Bin Liu,Yingchun Liu,Yuexin Liu,Yiling Lu,Gordon B. Mills,Sam Ng,Michael S. Noble,Evan O. Paull,Arvind Rao,Sheila Reynolds,Gordon Saksena,Zack Sanborn,Chris Sander,Nikolaus Schultz,Yasin Senbabaoglu,Ronglai Shen,Ilya Shmulevich,Rileen Sinha,Josh Stuart,S. Onur Sumer,Yichao Sun,Natalie Tasman,Barry S. Taylor,Doug Voet,Nils Weinhold,John N. Weinstein,Da Yang,Kosuke Yoshihara,Siyuan Zheng,Wei Zhang,Lihua Zou,Ty Abel,Sara Sadeghi,Mark L. Cohen,Jenny Eschbacher,Eyas M. Hattab,Aditya Raghunathan,Matthew Schniederjan,Dina Aziz,Gene Barnett,Wendi Barrett,Darell D. Bigner,Lori Boice,Cathy Brewer,Chiara Calatozzolo,Benito Campos,Carlos Gilberto Carlotti,Timothy A. Chan,Lucia Cuppini,Erin Curley,Stefania Cuzzubbo,Karen Devine,Francesco DiMeco,Rebecca Duell,J. Bradley Elder,Ashley Fehrenbach,Gaetano Finocchiaro,William A. Friedman,Jordonna Fulop,Johanna Gardner,Beth Hermes,Christel Herold-Mende,Christine Jungk,Ady Kendler,Norman L. Lehman,Eric S. Lipp,Ouida Liu,Randy Mandt,Mary McGraw,Roger E. McLendon,Christopher M. McPherson,Luciano Neder,Phuong L. Nguyen,Ardene Noss,Raffaele Nunziata,Quinn T. Ostrom,Cheryl A. Palmer,Alessandro Perin,Bianca Pollo,Alexander Potapov,Olga Potapova,W. Kimryn Rathmell,D L Rotin,Lisa Scarpace,Cathy Schilero,Kelly Senecal,Kristen Shimmel,Vsevolod Shurkhay,Suzanne Sifri,Rosy Singh,Andrew E. Sloan,Kathy Smolenski,Susan M. Staugaitis,Ruth Steele,Leigh B. Thorne,Daniela Pretti da Cunha Tirapelli,Andreas Unterberg,Mahitha Vallurupalli,Yun Wang,Ronald E. Warnick,Felicia Williams,Yingli Wolinsky,Sue E. Bell,Mara Rosenberg,Chip Stewart,Franklin W. Huang,Jonna Grimsby,Amie Radenbaugh,Jianan Zhang +306 more
TL;DR: The integration of genomewide data from multiple platforms delineated three molecular classes of lower-grade gliomas that were more concordant with IDH, 1p/19q, and TP53 status than with histologic class.
Journal ArticleDOI
Molecular Subgroups of Medulloblastoma: The Current Consensus
Michael D. Taylor,Paul A. Northcott,Andrey Korshunov,Marc Remke,Marc Remke,Yoon Jae Cho,Steven C. Clifford,Charles G. Eberhart,D. Williams Parsons,Stefan Rutkowski,Amar Gajjar,David W. Ellison,Peter Lichter,Richard J. Gilbertson,Scott L. Pomeroy,Marcel Kool,Stefan M. Pfister,Stefan M. Pfister +17 more
TL;DR: It is anticipated that the molecular classification of medulloblastoma will continue to evolve and diversify in the future as larger cohorts are studied at greater depth, and herein is outlined the current consensus nomenclature, and the differences between the medullOBlastoma subgroups.
Journal ArticleDOI
Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas
Gang Wu,Alberto Broniscer,Troy A. McEachron,Charles Lu,Barbara S. Paugh,Jared Becksfort,Chunxu Qu,Li Ding,Robert Huether,Matthew Parker,Junyuan Zhang,Amar Gajjar,Michael A. Dyer,Charles G. Mullighan,Richard J. Gilbertson,Elaine R. Mardis,Richard K. Wilson,James R. Downing,David W. Ellison,Jinghui Zhang,Suzanne J. Baker +20 more
TL;DR: To identify somatic mutations in pediatric diffuse intrinsic pontine glioma (DIPG), whole-genome sequencing of DNA from seven DIPGs and matched germline tissue and targeted sequencing of an additional 43 DIPG and 36 non-brainstem pediatric glioblastomas (non-BS-PGs) were performed.
Journal ArticleDOI
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas.
Hiroko Ohgaki,Paul Kleihues +1 more
TL;DR: Data is summarized on incidence rates, survival, and genetic alterations from population-based studies of astrocytic and oligodendrogliomas that were carried out in the Canton of Zurich, Switzerland to suggest that the acquisition of TP53 mutations in these glioblastoma subtypes may occur through different mechanisms.
Journal ArticleDOI
The Definition of Primary and Secondary Glioblastoma
Hiroko Ohgaki,Paul Kleihues +1 more
TL;DR: IDH1 mutations are the earliest detectable genetic alteration in precursor low-grade diffuse astrocytomas and in oligodendrogliomas, indicating that these tumors are derived from neural precursor cells that differ from those of primary glioblastomas.
Related Papers (5)
Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Roger Stupp,Warren P. Mason,Martin J. van den Bent,Michael Weller,Barbara Fisher,Martin J.B. Taphoorn,Karl Belanger,Alba A. Brandes,Christine Marosi,Ulrich Bogdahn,Jürgen Curschmann,Robert C. Janzer,Samuel K. Ludwin,Thierry Gorlia,Anouk Allgeier,Denis Lacombe,J. Gregory Cairncross,Elizabeth Eisenhauer,René O. Mirimanoff +18 more
IDH1 and IDH2 Mutations in Gliomas
Hai Yan,D. Williams Parsons,Genglin Jin,Roger E. McLendon,B.K. Ahmed Rasheed,Weishi Yuan,Ivan Kos,Ines Batinic-Haberle,Siân Jones,Gregory J. Riggins,Henry S. Friedman,Allan H. Friedman,David A. Reardon,James E. Herndon,Kenneth W. Kinzler,Victor E. Velculescu,Bert Vogelstein,Darell D. Bigner +17 more
Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1
Roel G.W. Verhaak,Katherine A. Hoadley,Elizabeth Purdom,Victoria Wang,Yuan-yuan Qi,Matthew D. Wilkerson,C. Ryan Miller,Li Ding,Todd R. Golub,Jill P. Mesirov,Gabriele Alexe,Michael S. Lawrence,Michael O'Kelly,Pablo Tamayo,Barbara A. Weir,Stacey Gabriel,Wendy Winckler,Supriya Gupta,Lakshmi Jakkula,Heidi S. Feiler,J. Graeme Hodgson,C. David James,Jann N. Sarkaria,Cameron Brennan,Ari B. Kahn,Paul T. Spellman,Richard K. Wilson,Terence P. Speed,Terence P. Speed,Joe W. Gray,Matthew Meyerson,Gad Getz,Charles M. Perou,Charles M. Perou,D. Neil Hayes +34 more